Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety powyżej 18 roku życia z przerzutowym rakiem piersi.
- •Rak piersi, który ma specyficzne cechy (ER+HER2-).
- •Obecność przerzutów w wątrobie i kościach widocznych na wcześniejszym badaniu PET.
- •Wykonanie badania PET z DOTATOC do 21 dni po poprzednim badaniu PET.
- •Zgoda na udział w badaniu.
✗ Disqualifies
- •Inne aktywne choroby nowotworowe.
- •Uczulenie na DOTATOC.
- •Osoby nieletnie.
- •Osoby uczestniczące w innym badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- March 4, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
CHU Grenoble Alpes
Grenoble, France
Trial contact
Marine FAURE
Pierre PITTET
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.